早期使用重组人干扰素-α1b雾化治疗手足口病的临床效果及对炎症反应的调控作用研究  

Study on the Clinical Effect of Early Application of Recombinant Human Interferon-α1b by Atomization Therapy in the Patients with Hand-foot-and-mouth Disease and Regulation Role for Inflammatory Response

作　　者：覃立刚 李宇生[1] 黄慧珠[1] 刘才华[1] QIN Ligang;LI Yusheng;HUANG Huizhu(Huizhou Second Maternal and Child Health Hospital,Huizhou 516003,China)

机构地区：[1]广东省惠州市第二妇幼保健院,广东惠州516003

出　　处：《中国医学创新》2019年第1期49-52,共4页Medical Innovation of China

基　　金：惠州市科技计划项目(20170403)

摘　　要：目的:分析早期使用重组人干扰素-α1b雾化治疗手足口病的临床效果及对炎症反应的调控作用。方法:选取2017年6月-2018年5月在本院诊治的92例手足口病患儿。按照随机数字表法将其分为对照组(常规手足口病治疗)和观察组(常规治疗联合重组人干扰素-α1b雾化治疗),各46例。比较两组临床疗效、症状体征(发热、口腔溃疡及手足皮疹)改善时间及治疗前后的血清炎性细胞因子水平(IL-1β、IL-6、IL-10)。结果:观察组治疗后3、7 d的临床总有效率分别为86.96%、100%,均高于对照组的69.57%、89.13%,比较差异均有统计学意义(P<0.05);观察组发热、口腔溃疡及手足皮疹改善时间均短于对照组,比较差异均有统计学意义(P<0.05);治疗后,观察组IL-1β、IL-6、IL-10水平均低于对照组,比较差异均有统计学意义(P<0.05)。结论:早期使用重组人干扰素-α1b雾化治疗手足口病的临床效果较好,且对炎症反应的调控作用也较为明显,因此适用于手足口病的临床治疗。Objective:To analyze the clinical effect of early application of Recombinant Human Interferon-α1b by atomization therapy in the patients with hand-foot-and-mouth disease and regulation role for inflammatory response.Method:A total of 92 children with hand-foot-and-mouth disease in our hospital from June 2017 to May 2018 were selected.According to the random number table method,they were divided into control group(routine treatment of hand-foot-and-mouth disease)and observation group(routine treatment combined with Recombinant Human Interferon-α1b by atomization therapy),46 cases in each group.The clinical efficacy,symptoms and signs(fever,oral ulcer and hand-foot rash)improvement time and serum inflammatory cytokine levels(IL-1β,IL-6,IL-10)before and after treatment between two groups were compared.Result:After treatment 3 and 7 days,the clinical total effective rates of observation group were 86.96%and 100%respectively,which were higher than 69.57%and 89.13%of control group,the differences were statistically significant(P<0.05).The improvement time of fever,oral ulcer and hand-foot rash in observation group were shorter than those of control group,the differences were statistically significant(P<0.05).After treatment,the levels of IL-1β,IL-6 and IL-10 in observation group were lower than those of control group,the differences were statistically significant(P<0.05).Conclusion:The clinical effect of early application of Recombinant Human Interferon-α1b by atomization therapy in the patients with hand-foot-and-mouth disease is better,and its regulation role for inflammatory response is obvious too,so it is suitable to the clinical treatment of hand-foot-and-mouth disease.

关 键 词：重组人干扰素-α1b 雾化治疗 手足口病 临床效果 炎症反应 

分 类 号：R725.1[医药卫生—儿科]